The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease.
Cognitive features, which begin before manifestation of the motor features, are an integral part of Huntington's disease and profoundly affect quality of life. A number of neuropsychological batteries have been used to assess this aspect of the condition, many of which are difficult to administer and time consuming, especially in advanced disease. We, therefore, investigated a simple and practical way to monitor cognition using the Addenbrooke's Cognitive Examination-Revised (ACE-R) in 126 manifest Huntington's disease patients, 28 premanifest gene carriers and 21 controls. Using this test, we demonstrated a selective decrease in phonemic, but not semantic, fluency in premanifest participants Cognitive decline in manifest Huntington's disease varied according to disease severity with extensive cognitive decline observed in early-stage Huntington's disease patients, indicating that this would be an optimal stage for interventions designed to halt cognitive decline, and lesser changes in the advanced cases. We next examined cognitive performance in patients prescribed antidopaminergic drugs as these drugs are known to decrease cognition when administered to healthy volunteers. We paradoxically found that these drugs may be beneficial, as early-stage Huntington's disease participants in receipt of them had improved attention and Mini-Mental State Examination scores. In conclusion, this is the first study to test the usefulness of the ACE-R in a Huntington's disease population and demonstrates that this is a brief, inexpensive and practical way to measure global cognitive performance in clinical practice with potential use in clinical trials.
Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK, fo228@cam.ac.uk.
Faye
F
Begeti
Adrian Y K
AY
Tan
Gemma A
GA
Cummins
Lucy M
LM
Collins
Natalie Valle
NV
Guzman
Sarah L
SL
Mason
Roger A
RA
Barker
D000328:Adult; D001288:Attention / Q000187:drug effects / Q000502:physiology; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications* / Q000235:genetics; D007802:Language; D008297:Male; D008568:Memory / Q000187:drug effects / Q000502:physiology; D008609:Mental Status Schedule; D008875:Middle Aged; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D013028:Space Perception / Q000187:drug effects / Q000502:physiology